Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events

Two abstracts accepted for oral presentation at the 13th London International Cough SymposiumNEW HAVEN, Conn., July 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage bi

Trevi TherapeuticsJul 2 00:00 ET

Here's Why We're Not Too Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Situation

Yahoo FinanceJun 27 10:34 ET

Trevi Therapeutics Initiated at Buy by Rodman & Renshaw

Trevi Therapeutics Initiated at Buy by Rodman & Renshaw

Dow JonesJun 13 13:50 ET

Rodman & Renshaw Initiates Coverage On Trevi Therapeutics With Buy Rating, Announces Price Target of $7

Rodman & Renshaw analyst Brandon Folkes initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Buy rating and announces Price Target of $7.

BenzingaJun 13 13:40 ET

Rodman & Renshaw Initiates Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $7

Rodman & Renshaw analyst Elemer Piros initiates coverage on $Trevi Therapeutics(TRVI.US)$ with a buy rating, and sets the target price at $7.According to TipRanks data, the analyst has a success rate

moomoo NewsJun 12 18:32 ET · Ratings

12 Health Care Stocks Moving In Thursday's After-Market Session

GainersVenus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. The market value of their outstanding shares is at $9.0 million. Cyclacel Pharmaceuticals (NASDAQ:

BenzingaJun 6 16:31 ET